Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Thermo Fisher Scientific has released the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center in collaboration with Massachusetts General Hospital (MGH), Harvard University.
Subscribe to our email newsletter
The research, conducted using Thermo Scientific mass spectrometers, provides insight into key areas of stroke evaluation and treatment.
The collaboration between the BRIMS Center and Harvard University has also led to potential insights in the understanding of tissue plasminogen activator (tPA), a drug that can be safely administered only within a very short time window after stroke symptoms occur.
The research is led by MingMing Ning, a clinical neurologist and researcher at the Clinical Proteomics Research Center at MGH.
It provides potentially significant new insight into patent foramen ovale (PFO) and its connection with strokes.
Identification of potential biomarkers in mass spec data derived from the collaborative research provides scientists with new insights into how PFO can be related to strokes.
If confirmed, these insights may be important in helping doctors to select the most appropriate treatment for individual PFO stroke patients.
Ning said the collaboration between Mary Lopez and her team at the BRIMS Center; Dr Tom Jacobs at NIH/NINDS; and Dr Eng H Lo, Dr Ferdinando Buonanno and Dr Anne Young at the Clinical Proteomics Research Center at MGH has allowed them to build a crucial bridge from research to treatment, enabling them to gather key research information in real-time.